Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription Articles published in Oncogene Retrieve available abstracts of 85 articles: HTML format

Single Articles

October 2026
1. TANG Q, Slarve I, Chen J, Zeng N, et al
   PTEN-AKT2 regulates mixed lineage liver cancer development and sensitizes cancer cells to TGFbeta treatment.
   Oncogene. 2026;45:4362-4376.
   PubMed     Abstract available
   
   
   September 2026
2. VARADHARAJ V, Leon F, Krishna Kumar N, Nallasamy P, et al
   Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis.
   Oncogene. 2026;45:3858-3873.
   PubMed     Abstract available
   
   
   August 2026
3. JEON S, Shin E, Ha JW, Na MJ, et al
   CSTF2-mediated 3'UTR shortening drives oncogenic activation of GPC3 in hepatocellular carcinoma.
   Oncogene. 2026 Aug 10. doi: 10.1038/s41388-026-03937.
   PubMed     Abstract available
   
   
   
4. SU T, Liao J, Dai Z, Xu L, et al
   Correction: Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation.
   Oncogene. 2026 Aug 4. doi: 10.1038/s41388-026-03950.
   PubMed    
   
   
   
5. ZHANG H, Kong X, Qu H, Gao Y, et al
   Correction: MYCBP2-mediated HNF4alpha ubiquitination reprogrammed lipid metabolism in MASH-associated hepatocellular carcinoma.
   Oncogene. 2026 Aug 3. doi: 10.1038/s41388-026-03948.
   PubMed    
   
   
   
6. XU Y, Li JJ, Zhou LE, Liu HH, et al
   Matrix stiffness drives HCC invasion and metastasis via interfering with TRIM21-mediated SCD1 ubiquitination.
   Oncogene. 2026;45:3230-3243.
   PubMed     Abstract available
   
   
   July 2026
7. HUANG H, Huang C, Yang P, Xian S, et al
   The epigenetic KMT5C-HDAC1 axis promotes hepatocellular carcinoma stemness and progression through SERPINA4 repression and chromatin compaction.
   Oncogene. 2026 Jul 27. doi: 10.1038/s41388-026-03920.
   PubMed     Abstract available
   
   
   
8. DU Y, Zhang XF, Wu S, Zheng J, et al
   PTP4A3 dephosphorylates EGFR to promote metastasis and enhance sensitivity to lapatinib in hepatocellular carcinoma.
   Oncogene. 2026 Jul 8. doi: 10.1038/s41388-026-03866.
   PubMed     Abstract available
   
   
   
9. LANG Q, Yin Z, Sun J, Wang Y, et al
   Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.
   Oncogene. 2026 Jul 2. doi: 10.1038/s41388-026-03874.
   PubMed     Abstract available
   
   
   June 2026
10. XIAO Y, He Z, Al-Subari MH, Zhang H, et al
    MOV10 suppresses circRNA biogenesis by disrupting reverse complementary matches structure to drive hepatocarcinogenesis.
    Oncogene. 2026 Jun 21. doi: 10.1038/s41388-026-03869.
    PubMed     Abstract available
    
    
    
11. ZHANG C, Chen X, Yao H, Chen Y, et al
    STK39 promotes the evolution cascade of hepatocellular carcinoma by facilitating PKR/NF-kappaB-mediated macrophage inflammatory response.
    Oncogene. 2026 Jun 13. doi: 10.1038/s41388-026-03859.
    PubMed     Abstract available
    
    
    
12. WANG D, Jin K, Ying C, Li B, et al
    Intratumoral bicarbonate functions as an adjuvant to potentiate PD-1 blockade in hepatocellular carcinoma.
    Oncogene. 2026 Jun 5. doi: 10.1038/s41388-026-03836.
    PubMed     Abstract available
    
    
    
13. DAI Q, Lou L, Zhu X, Zhao H, et al
    TIAL1 regulates the Hippo pathway through an RNA-binding-independent mechanism.
    Oncogene. 2026;45:1941-1951.
    PubMed     Abstract available
    
    
    
14. ZHONG Y, Zhou X, Zhou Y, Shi H, et al
    PSPC1-AS2/PSPC1 axis drives STAT3-dependent CCL2 expression to promote M2 macrophage polarization and liver metastasis in gastric cancer.
    Oncogene. 2026;45:2014-2028.
    PubMed     Abstract available
    
    
    May 2026
15. WAN Q, Li J, Guo M, Hu J, et al
    GPX8(+) cancer-associated fibroblast-derived lactate contributes to lenvatinib resistance by facilitating BRPF1 expression through histone H3 lysine 18 lactylation in hepatocellular carcinoma.
    Oncogene. 2026 May 22. doi: 10.1038/s41388-026-03711.
    PubMed     Abstract available
    
    
    
16. KITISIN K, Ganesan N, Tang Y, Jogunoori W, et al
    Editorial Expression of Concern: Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation.
    Oncogene. 2026 May 11. doi: 10.1038/s41388-026-03821.
    PubMed    
    
    
    April 2026
17. XING H, Ma F, Li P, Xuan M, et al
    METTL1-mediated m(7)G modification of ASNS mRNA regulates asparagine metabolism reprogramming to promote hepatocellular carcinoma progression.
    Oncogene. 2026 Apr 27. doi: 10.1038/s41388-026-03806.
    PubMed     Abstract available
    
    
    
18. LV C, Du J, Feng W, Zhou R, et al
    Modulating gut microbiota to enhance anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: the role of Lactobacillus kefiranofaciens and SOCS3 regulation.
    Oncogene. 2026 Apr 27. doi: 10.1038/s41388-026-03701.
    PubMed     Abstract available
    
    
    
19. ZONG W, Cheng C, Zhang Y, Lu Y, et al
    GOT1 inhibits hepatocellular carcinoma progression by regulating SLC25A5-dependent mitochondrial apoptosis.
    Oncogene. 2026 Apr 14. doi: 10.1038/s41388-026-03769.
    PubMed     Abstract available
    
    
    
20. WANG F, Huang M, Sheng K, Yan Y, et al
    Dual inhibition of glycolysis and glutaminolysis by targeting FOXO3 for hepatocellular carcinoma treatment.
    Oncogene. 2026 Apr 13. doi: 10.1038/s41388-026-03765.
    PubMed     Abstract available
    
    
    
21. SHEN Z, Yang Y, Mao T, Wu F, et al
    Plasmin promotes hepatocellular carcinoma invasion and metastasis via CXCR4-mediated activation of PI3K/AKT/mTOR signaling.
    Oncogene. 2026 Apr 9. doi: 10.1038/s41388-026-03775.
    PubMed     Abstract available
    
    
    
22. JIAO Q, Ren Y, Su X, Li Z, et al
    SETDB2 induces abnormal SHP-1 splicing and promotes immunosuppression in hepatocellular carcinoma.
    Oncogene. 2026 Apr 7. doi: 10.1038/s41388-026-03759.
    PubMed     Abstract available
    
    
    
23. LI Y, Zheng C, Liang Y, Liu Y, et al
    S100A6 promotes liver metastasis by activating FGFR3 signaling in BAP1-deficient uveal melanoma.
    Oncogene. 2026 Apr 4. doi: 10.1038/s41388-026-03766.
    PubMed     Abstract available
    
    
    March 2026
24. XU S, Gong R, Liu S, Wang J, et al
    Dual function of DOT1L suppresses tumor cell-intrinsic immunogenicity in hepatocellular carcinoma.
    Oncogene. 2026 Mar 31. doi: 10.1038/s41388-026-03744.
    PubMed     Abstract available
    
    
    
25. WANG M, Hong G, Zhang C, Xiao Y, et al
    CAPRIN1-mediated sequestration of NCOA4 mRNA into stress granules drives sorafenib resistance in hepatocellular carcinoma.
    Oncogene. 2026 Mar 28. doi: 10.1038/s41388-026-03750.
    PubMed     Abstract available
    
    
    
26. DENG R, Zheng X, Liu F, Gao J, et al
    The NPC1/USP7/p53 axis regulates cholesterol and promotes the proliferation of hepatocellular carcinoma.
    Oncogene. 2026 Mar 26. doi: 10.1038/s41388-026-03739.
    PubMed     Abstract available
    
    
    January 2026
27. TAYA M, Fishman D, Kanani F, Zinger L, et al
    The role of the SLC25A15 transporter in the formation of liver metastasis in ESR1-mutated breast cancer.
    Oncogene. 2026 Jan 3. doi: 10.1038/s41388-025-03640.
    PubMed     Abstract available
    
    
    December 2025
28. ZHANG Y, Xiong C, Jiang Z, Wang X, et al
    Unveiling EMC6 as a novel pathogenic determinant in hepatocellular carcinoma: orchestration of lipid metabolism through regulation of lipid droplet-associated enzyme HSD17B13.
    Oncogene. 2025 Dec 3. doi: 10.1038/s41388-025-03649.
    PubMed     Abstract available
    
    
    November 2025
29. CHEN W, Lin C, Wang L, Yu Z, et al
    Hepatitis B virus X protein promotes the progression and immune escape of hepatocellular carcinoma by activating KLF16-C12orf49-PD-L1 axis.
    Oncogene. 2025 Nov 14. doi: 10.1038/s41388-025-03625.
    PubMed     Abstract available
    
    
    
30. HUANG H, Xiang Y, Deng Y, Liu Q, et al
    WBP11 inhibits UFL1-mediated UFMylation of NONO to drive hepatocellular carcinoma progression.
    Oncogene. 2025 Nov 3. doi: 10.1038/s41388-025-03620.
    PubMed     Abstract available
    
    
    October 2025
31. CHEN Q, Liang Y, Li Y, Li X, et al
    PSME3 drives Tregs infiltration and anti-PD1 resistance in hepatocellular carcinoma by regulating FBXL7/PTEN-mediated metabolic reprogramming.
    Oncogene. 2025 Oct 15. doi: 10.1038/s41388-025-03593.
    PubMed     Abstract available
    
    
    
32. TSUCHIYA H, Hanaki T, Sakabe T, Tokuyasu N, et al
    Immune evasion from macrophages by NEAT1-induced CD24 in liver cancer.
    Oncogene. 2025;44:3652-3664.
    PubMed     Abstract available
    
    
    September 2025
33. LI J, Mao S, Yang S, Lou Y, et al
    Targeting JMJD6/PPARgamma/GPX4 axis overcomes ferroptosis resistance and enhances therapeutic efficacy in hepatocellular carcinoma.
    Oncogene. 2025 Sep 30. doi: 10.1038/s41388-025-03581.
    PubMed     Abstract available
    
    
    
34. WU Z, Duan W, Xiong Y, Liu J, et al
    Publisher Correction: NeuroD1 drives a KAT2A-FDFT1 signaling axis to promote cholesterol biosynthesis and hepatocellular carcinoma progression via histone H3K27 acetylation.
    Oncogene. 2025 Sep 22. doi: 10.1038/s41388-025-03574.
    PubMed    
    
    
    
35. ZHAO J, Cui M, Yao X, Jiang Z, et al
    Targeting TFAM downregulation mediated mtDNA-NLRP3 pathway suppresses TAM infiltration and HCC progression.
    Oncogene. 2025;44:2956-2969.
    PubMed     Abstract available
    
    
    
36. WU Z, Duan W, Xiong Y, Liu J, et al
    NeuroD1 drives a KAT2A-FDFT1 signaling axis to promote cholesterol biosynthesis and hepatocellular carcinoma progression via histone H3K27 acetylation.
    Oncogene. 2025 Sep 1. doi: 10.1038/s41388-025-03534.
    PubMed     Abstract available
    
    
    August 2025
37. SUN C, Cai S, Yang J, Du M, et al
    OTUB1 antagonizes TRIM21 to induce deubiquitination of SPHK1 and promote the progression of hepatocellular carcinoma.
    Oncogene. 2025 Aug 30. doi: 10.1038/s41388-025-03556.
    PubMed     Abstract available
    
    
    
38. HAN H, Gong C, Zhang Y, Liu C, et al
    RBM30 recruits DOT1L to activate STAT1 transcription and drive immune evasion in hepatocellular carcinoma.
    Oncogene. 2025 Aug 29. doi: 10.1038/s41388-025-03550.
    PubMed     Abstract available
    
    
    
39. HAN J, Wang F, Lan Y, Wang J, et al
    Retraction Note to: KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.
    Oncogene. 2025 Aug 11. doi: 10.1038/s41388-025-03527.
    PubMed    
    
    
    July 2025
40. GUO S, Zhang Q, Ma J, Zou Y, et al
    PABPN1-C5 axis promotes hepatocellular carcinoma progression via NF-kappaB activation.
    Oncogene. 2025 Jul 28. doi: 10.1038/s41388-025-03501.
    PubMed     Abstract available
    
    
    May 2025
41. GENG X, Li M, Zhang L, Cai Y, et al
    P5CS deacetylation mediated by SIRT2 facilitates tumor growth by enhancing mitochondrial respiration in hepatocellular carcinoma.
    Oncogene. 2025 May 27. doi: 10.1038/s41388-025-03456.
    PubMed     Abstract available
    
    
    
42. SOUDAH N, Baskin A, Darash-Yahana M, Darlyuk-Saadon I, et al
    Erk1(R84H) is an oncoprotein that causes hepatocellular carcinoma in mice and imposes a rigorous negative feedback loop.
    Oncogene. 2025 May 20. doi: 10.1038/s41388-025-03437.
    PubMed     Abstract available
    
    
    
43. DENG L, Tang J, Yang H, Cheng C, et al
    Retraction Note: MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway.
    Oncogene. 2025 May 12. doi: 10.1038/s41388-025-03433.
    PubMed    
    
    
    
44. SHU Y, Tao Q, Xu Q, Chen Y, et al
    Loss of NUMB promotes hepatomegaly and hepatocellular carcinoma through the AKT/glycogen/hippo signaling.
    Oncogene. 2025 May 3. doi: 10.1038/s41388-025-03430.
    PubMed     Abstract available
    
    
    
45. SHA N, Zhou B, Hou G, Xi Z, et al
    The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation.
    Oncogene. 2025;44:1078-1092.
    PubMed     Abstract available
    
    
    April 2025
46. HU H, Zhan X, Xiong Y, Yuan R, et al
    Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through destabilizing cytoplasmic KDM3A.
    Oncogene. 2025 Apr 19. doi: 10.1038/s41388-025-03410.
    PubMed     Abstract available
    
    
    
47. ZHANG H, Kong X, Qu H, Gao Y, et al
    MYCBP2-mediated HNF4alpha ubiquitination reprogrammed lipid metabolism in MASH-associated hepatocellular carcinoma.
    Oncogene. 2025 Apr 3. doi: 10.1038/s41388-025-03373.
    PubMed     Abstract available
    
    
    
48. LI D, Gao Z, Zhang Z, Chen H, et al
    Suprabasin promotes gastric cancer liver metastasis via hepatic stellate cells-mediated EGF/CCL2/JAK2 intercellular signaling pathways.
    Oncogene. 2025 Apr 3. doi: 10.1038/s41388-025-03370.
    PubMed     Abstract available
    
    
    
49. ZHANG GP, Song ZB, Chen DH, Yu Y, et al
    Syntaxin-6 mediated autophagy confers lenvatinib resistance in hepatocellular carcinoma.
    Oncogene. 2025 Apr 3. doi: 10.1038/s41388-025-03371.
    PubMed     Abstract available
    
    
    
50. LU Y, Li X, Liu H, Xue J, et al
    Retraction Note: beta-Trcp and CK1delta-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma.
    Oncogene. 2025;44:931.
    PubMed    
    
    
    March 2025
51. JIANG S, Jiang L, Xu Y, Ma Y, et al
    USP5 deubiquitinates and stabilizes IMPDH2, to promote hepatocellular carcinoma progression.
    Oncogene. 2025 Mar 31. doi: 10.1038/s41388-025-03355.
    PubMed     Abstract available
    
    
    
52. ZHOU J, Wang J, Yang L, Fu T, et al
    N6-methyadenosine-modified YWHAE mRNA promotes proliferation and inhibits ferroptosis in hepatoblastoma by mediating SLC7A11 expression.
    Oncogene. 2025 Mar 12. doi: 10.1038/s41388-025-03334.
    PubMed     Abstract available
    
    
    
53. ZHU J, Wang L, Nie X, Ou S, et al
    RBMS3-loss impedes TRIM21-induced ubiquitination of ANGPT2 in an RNA-independent manner and drives sorafenib resistance in hepatocellular carcinoma.
    Oncogene. 2025 Mar 11. doi: 10.1038/s41388-025-03335.
    PubMed     Abstract available
    
    
    
54. LIANG Y, Qiao L, Qian Q, Zhang R, et al
    Integrated single-cell and spatial transcriptomic profiling reveals that CD177(+) Tregs enhance immunosuppression through apoptosis and resistance to immunotherapy in hepatocellular carcinoma.
    Oncogene. 2025 Mar 7. doi: 10.1038/s41388-025-03330.
    PubMed     Abstract available
    
    
    
55. ZHANG B, Zhou Y, Xu X, Xu G, et al
    RBM39 promotes hepatocarcinogenesis by regulating RFX1's alternative splicing and subsequent activation of integrin signaling pathway.
    Oncogene. 2025 Mar 3. doi: 10.1038/s41388-025-03327.
    PubMed     Abstract available
    
    
    
56. XU J, Li Y, Wang G, Chen D, et al
    Impaired mitochondrial degradation of CHCHD2 promotes metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma by upregulating VEGFA.
    Oncogene. 2025 Mar 1. doi: 10.1038/s41388-025-03321.
    PubMed     Abstract available
    
    
    February 2025
57. LI Y, Ouyang Q, Chen Z, Zhou D, et al
    Novel role of general transcript factor IIH subunit 2 (GTF2H2) in the development and sex disparity of hepatocellular carcinoma.
    Oncogene. 2025 Feb 19. doi: 10.1038/s41388-025-03301.
    PubMed     Abstract available
    
    
    November 2024
58. ZHUANG M, Liu J, Li Y, Zhang J, et al
    PD-L1 promotes tumor metastasis by regulating the infiltration of FGFBP2(+)Tm cells in colorectal cancer.
    Oncogene. 2024 Nov 18. doi: 10.1038/s41388-024-03223.
    PubMed     Abstract available
    
    
    October 2024
59. XING H, Gu X, Liu Y, Xu L, et al
    NSUN2 regulates Wnt signaling pathway depending on the m5C RNA modification to promote the progression of hepatocellular carcinoma.
    Oncogene. 2024 Oct 7. doi: 10.1038/s41388-024-03184.
    PubMed     Abstract available
    
    
    
60. LI X, Hu Z, Shi Q, Qiu W, et al
    Elevated choline drives KLF5-dominated transcriptional reprogramming to facilitate liver cancer progression.
    Oncogene. 2024;43:3121-3136.
    PubMed     Abstract available
    
    
    
61. LIU Z, Hu Q, Luo Q, Zhang G, et al
    NUP37 accumulation mediated by TRIM28 enhances lipid synthesis to accelerate HCC progression.
    Oncogene. 2024;43:3255-3267.
    PubMed     Abstract available
    
    
    September 2024
62. XIE P, Wu M, Wang H, Zhang B, et al
    GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma.
    Oncogene. 2024 Sep 9. doi: 10.1038/s41388-024-03153.
    PubMed     Abstract available
    
    
    
63. DU J, Bai D, Gu C, Zhao J, et al
    Sorafenib-mediated cleavage of p62 initiates cellular senescence as a mechanism to evade its anti-hepatocellular carcinoma efficacy.
    Oncogene. 2024 Sep 4. doi: 10.1038/s41388-024-03142.
    PubMed     Abstract available
    
    
    August 2024
64. HAN H, Shi Q, Zhang Y, Ding M, et al
    RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation.
    Oncogene. 2024 Aug 26. doi: 10.1038/s41388-024-03140.
    PubMed     Abstract available
    
    
    
65. CUI M, Liu Z, Wang S, Bae S, et al
    CRISPR-based dissection of microRNA-23a ~ 27a ~ 24-2 cluster functionality in hepatocellular carcinoma.
    Oncogene. 2024 Aug 7. doi: 10.1038/s41388-024-03115.
    PubMed     Abstract available
    
    
    
66. TANG X, Gao L, Jiang X, Hou Z, et al
    Single-cell profiling reveals altered immune landscape and impaired NK cell function in gastric cancer liver metastasis.
    Oncogene. 2024;43:2635-2646.
    PubMed     Abstract available
    
    
    July 2024
67. ZHANG T, Zhao F, Hu Y, Wei J, et al
    Environmental monobutyl phthalate exposure promotes liver cancer via reprogrammed cholesterol metabolism and activation of the IRE1alpha-XBP1s pathway.
    Oncogene. 2024;43:2355-2370.
    PubMed     Abstract available
    
    
    
68. LI W, Guo Z, Zhou Z, Zhou Z, et al
    Distinguishing high-metastasis-potential circulating tumor cells through fluidic shear stress in a bloodstream-like microfluidic circulatory system.
    Oncogene. 2024;43:2295-2306.
    PubMed     Abstract available
    
    
    June 2024
69. GU J, Xu X, Li X, Yue L, et al
    Tumor-resident microbiota contributes to colorectal cancer liver metastasis by lactylation and immune modulation.
    Oncogene. 2024 Jun 18. doi: 10.1038/s41388-024-03080.
    PubMed     Abstract available
    
    
    
70. KE R, Viswakarma N, Menhart M, Singh SK, et al
    MLK3 promotes prooncogenic signaling in hepatocellular carcinoma via TGFbeta pathway.
    Oncogene. 2024 Jun 10. doi: 10.1038/s41388-024-03055.
    PubMed     Abstract available
    
    
    
71. LI X, He W, Chen X, Zhang Y, et al
    TRIM45 facilitates NASH-progressed HCC by promoting fatty acid synthesis via catalyzing FABP5 ubiquitylation.
    Oncogene. 2024;43:2063-2077.
    PubMed     Abstract available
    
    
    March 2024
72. DENG T, Zhao J, Tong Y, Chen Z, et al
    Crosstalk between endothelial progenitor cells and HCC through periostin/CCL2/CD36 supports formation of the pro-metastatic microenvironment in HCC.
    Oncogene. 2024;43:944-961.
    PubMed     Abstract available
    
    
    February 2024
73. ZHANG T, Zhao F, Zhang Y, Shi JH, et al
    Targeting the IRE1alpha-XBP1s axis confers selective vulnerability in hepatocellular carcinoma with activated Wnt signaling.
    Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02988.
    PubMed     Abstract available
    
    
    
74. FENG Z, Yin J, Zhang Z, Chen Z, et al
    O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation.
    Oncogene. 2024 Feb 23. doi: 10.1038/s41388-024-02977.
    PubMed     Abstract available
    
    
    
75. LI B, Xiong X, Xu J, Peng D, et al
    METTL3-mediated m(6)A modification of lncRNA TSPAN12 promotes metastasis of hepatocellular carcinoma through SENP1-depentent deSUMOylation of EIF3I.
    Oncogene. 2024 Feb 19. doi: 10.1038/s41388-024-02970.
    PubMed     Abstract available
    
    
    January 2024
76. GENG L, Zhu M, Luo D, Chen H, et al
    TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinoma.
    Oncogene. 2024 Jan 12. doi: 10.1038/s41388-023-02935.
    PubMed     Abstract available
    
    
    
77. GU X, Li P, Gao X, Ru Y, et al
    RNA 5-methylcytosine writer NSUN5 promotes hepatocellular carcinoma cell proliferation via a ZBED3-dependent mechanism.
    Oncogene. 2024 Jan 5. doi: 10.1038/s41388-023-02931.
    PubMed     Abstract available
    
    
    December 2023
78. WANG C, Chen Z, Yi Y, Ding Y, et al
    RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4.
    Oncogene. 2023 Dec 1. doi: 10.1038/s41388-023-02902.
    PubMed     Abstract available
    
    
    November 2023
79. CAO K, Wang R, Li L, Liao Y, et al
    Targeting DDX11 promotes PARP inhibitor sensitivity in hepatocellular carcinoma by attenuating BRCA2-RAD51 mediated homologous recombination.
    Oncogene. 2023 Nov 25. doi: 10.1038/s41388-023-02898.
    PubMed     Abstract available
    
    
    
80. CHEN J, Ning D, Du P, Liu Q, et al
    USP11 potentiates HGF/AKT signaling and drives metastasis in hepatocellular carcinoma.
    Oncogene. 2023 Nov 16. doi: 10.1038/s41388-023-02847.
    PubMed     Abstract available
    
    
    
81. LIU F, Liao Z, Zhang Z
    MYC in liver cancer: mechanisms and targeted therapy opportunities.
    Oncogene. 2023;42:3303-3318.
    PubMed     Abstract available
    
    
    September 2023
82. ZHOU J, Xu W, Wu Y, Wang M, et al
    GPR37 promotes colorectal cancer liver metastases by enhancing the glycolysis and histone lactylation via Hippo pathway.
    Oncogene. 2023 Sep 25. doi: 10.1038/s41388-023-02841.
    PubMed     Abstract available
    
    
    
83. YU A, Yu P, Zhu Y, Zhu R, et al
    Glucose-induced and ChREBP: MLX-mediated lipogenic program promotes hepatocellular carcinoma development.
    Oncogene. 2023 Sep 9. doi: 10.1038/s41388-023-02831.
    PubMed     Abstract available
    
    
    
84. DU D, Qin M, Shi L, Liu C, et al
    RNA binding motif protein 45-mediated phosphorylation enhances protein stability of ASCT2 to promote hepatocellular carcinoma progression.
    Oncogene. 2023 Sep 1. doi: 10.1038/s41388-023-02795.
    PubMed     Abstract available
    
    
    
85. QIAO X, Lin J, Shen J, Chen Y, et al
    FBXO28 suppresses liver cancer invasion and metastasis by promoting PKA-dependent SNAI2 degradation.
    Oncogene. 2023;42:2878-2891.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum